GlassScriptPhysician profile
Oksana Volod
NPI 1619199312
$53,958.84
in general payments reported to CMS, 2019-2025
6 companies · $2,236 in 2025
The $2,236 reported for 2025 was more than what 91% of Anatomic Pathology & Clinical Pathology providers received nationally (typical 2025 total: $50.59).
See the full distribution for Anatomic Pathology & Clinical Pathology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $17K · 2020: $14K · 2021: $5,744 · 2022: $5,788 · 2023: $1,371 · 2024: $7,874 · 2025: $2,236.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $5,626 · Consulting Fee: $5,250 · Food and Beverage: $604.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $5,626.13 |
| Consulting Fee | $5,250.00 |
| Food and Beverage | $604.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Diagnostica Stago, INC | $26,332.13 | 2019-2025 | |
| Haemonetics Corporation | $12,861.62 | 2019-2020 | |
| Abbott Laboratories | $12,390.35 | 2019-2023 | Afinion 2 |
| Alexion Pharmaceuticals, INC. | $1,248.22 | 2019-2025 | Ultomiris, Soliris |
| Hemosonics LLC | $1,000.00 | 2021 | |
| Blueprint Medicines Corporation | $126.52 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Oksana Volod listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.